CA2380786A1 - 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents - Google Patents

3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents Download PDF

Info

Publication number
CA2380786A1
CA2380786A1 CA002380786A CA2380786A CA2380786A1 CA 2380786 A1 CA2380786 A1 CA 2380786A1 CA 002380786 A CA002380786 A CA 002380786A CA 2380786 A CA2380786 A CA 2380786A CA 2380786 A1 CA2380786 A1 CA 2380786A1
Authority
CA
Canada
Prior art keywords
pyrazol
cyclopropyl
urea
amino
phenethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380786A
Other languages
English (en)
French (fr)
Inventor
Paolo Pevarello
Paolo Orsini
Gabriella Traquandi
Mario Varasi
Edward L. Fritzen
Martha A. Warpehoski
Betsy S. Pierce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2380786A1 publication Critical patent/CA2380786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002380786A 1999-08-12 2000-08-11 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents Abandoned CA2380786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/372,833 US6387900B1 (en) 1999-08-12 1999-08-12 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US09/372,833 1999-08-12
PCT/US2000/017878 WO2001012188A1 (en) 1999-08-12 2000-08-11 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
CA2380786A1 true CA2380786A1 (en) 2001-02-22

Family

ID=23469810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380786A Abandoned CA2380786A1 (en) 1999-08-12 2000-08-11 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Country Status (25)

Country Link
US (1) US6387900B1 (US20050059668A1-20050317-C00061.png)
EP (1) EP1202734B1 (US20050059668A1-20050317-C00061.png)
JP (1) JP2003507328A (US20050059668A1-20050317-C00061.png)
KR (1) KR20020060158A (US20050059668A1-20050317-C00061.png)
CN (1) CN1379668A (US20050059668A1-20050317-C00061.png)
AR (1) AR035557A1 (US20050059668A1-20050317-C00061.png)
AT (1) ATE361070T1 (US20050059668A1-20050317-C00061.png)
AU (1) AU6747000A (US20050059668A1-20050317-C00061.png)
BR (1) BR0013277A (US20050059668A1-20050317-C00061.png)
CA (1) CA2380786A1 (US20050059668A1-20050317-C00061.png)
CO (1) CO5200848A1 (US20050059668A1-20050317-C00061.png)
DE (1) DE60034683T2 (US20050059668A1-20050317-C00061.png)
EA (1) EA200200249A1 (US20050059668A1-20050317-C00061.png)
ES (1) ES2284518T3 (US20050059668A1-20050317-C00061.png)
HK (1) HK1049790A1 (US20050059668A1-20050317-C00061.png)
HU (1) HUP0301857A2 (US20050059668A1-20050317-C00061.png)
IL (1) IL147925A0 (US20050059668A1-20050317-C00061.png)
MX (1) MXPA02001497A (US20050059668A1-20050317-C00061.png)
NO (1) NO20020687L (US20050059668A1-20050317-C00061.png)
NZ (1) NZ517238A (US20050059668A1-20050317-C00061.png)
PE (1) PE20010482A1 (US20050059668A1-20050317-C00061.png)
PL (1) PL354058A1 (US20050059668A1-20050317-C00061.png)
SK (1) SK2082002A3 (US20050059668A1-20050317-C00061.png)
WO (1) WO2001012188A1 (US20050059668A1-20050317-C00061.png)
ZA (1) ZA200201118B (US20050059668A1-20050317-C00061.png)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2699568C (en) 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
AU2972701A (en) * 2000-02-07 2001-08-14 Bristol Myers Squibb Co 3-aminopyrazole inhibitors of cyclin dependent kinases
JP2004507455A (ja) 2000-04-25 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
AU2001280009A1 (en) * 2000-08-31 2002-03-13 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
PT2305255E (pt) † 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
KR20030071029A (ko) * 2002-02-27 2003-09-03 주식회사 팜제니아 항암제 및 방사선 치료 증진제로서 유용한 조성물
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
MXPA04011417A (es) * 2002-05-17 2005-02-14 Pharmacia Italia Spa Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
MXPA05002493A (es) * 2002-09-05 2005-05-27 Neurosearch As Derivados de diarilurea y su uso como bloqueadores del canal del cloro.
CA2501799C (en) * 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
GEP20094664B (en) 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
RS52625B (en) 2003-07-23 2013-06-28 Bayer Healthcare Llc FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EP1609789A1 (en) * 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
NZ552868A (en) * 2004-08-12 2009-07-31 Pfizer Triazolopyridinylsulfanyl derivatives as P38 MAP kinase inhibitors
US7598249B2 (en) 2004-12-30 2009-10-06 Janssen Pharmaceutica N.V. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7429800B2 (en) * 2005-06-30 2008-09-30 Sabic Innovative Plastics Ip B.V. Molding composition and method, and molded article
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
WO2007129052A1 (en) * 2006-05-03 2007-11-15 Astrazeneca Ab Pyrazole derivatives and their use as pi3k inhibitors
EP2091943B1 (en) 2006-10-21 2013-11-20 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP5675343B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
MX2009012765A (es) * 2007-05-25 2009-12-16 Janssen Pharmaceutica Nv Moduladores de urea con heteroarilo sustituido de acido graso amida hidrolasa.
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
US20110224221A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) * 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US20120100100A1 (en) 2009-05-13 2012-04-26 Sharpless Norman E Cyclin dependent kinase inhibitors and methods of use
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
JP2013531801A (ja) * 2010-07-02 2013-08-08 ヴェンタナ メディカル システムズ， インク． 標的検出のためのハプテンコンジュゲート
CA2806634A1 (en) * 2010-08-20 2012-02-23 Gruenenthal Gmbh Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
PL2922844T3 (pl) 2012-11-13 2018-06-29 Array Biopharma, Inc. N-pirolidynyl, n’-pirazolilowe związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny jako inhibitory kinazy trka
WO2014078331A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP6345684B2 (ja) 2012-11-13 2018-06-20 アレイ バイオファーマ、インコーポレイテッド 疼痛の治療に有用な二環式尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
EP2968291A4 (en) 2013-03-15 2016-09-28 G1 Therapeutics Inc HSPC-PROOF TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
JP6499672B2 (ja) 2014-05-15 2019-04-10 アレイ バイオファーマ、インコーポレイテッド ＴｒｋＡキナーゼ阻害剤としての１−（（３Ｓ，４Ｒ）−４−（３−フルオロフェニル）−１−（２−メトキシエチル）ピロリジン−３−イル）−３−（４−メチル−３−（２−メチルピリミジン−５−イル）−１−フェニル−１Ｈ−ピラゾール−５−イル）尿素
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3754887A (en) * 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US3646059A (en) * 1969-05-05 1972-02-29 Du Pont Plant growth regulatory ureidopyrazoles
DE69532817T2 (de) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
DE69720051T2 (de) * 1996-12-03 2003-09-04 Banyu Pharmaceutical Co., Ltd. Harnstoffderivate
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
JP4403482B2 (ja) 1997-12-22 2010-01-27 バイエル コーポレイション 置換複素環尿素合成のための中間体およびその製造方法

Also Published As

Publication number Publication date
US6387900B1 (en) 2002-05-14
ATE361070T1 (de) 2007-05-15
ES2284518T3 (es) 2007-11-16
SK2082002A3 (en) 2002-09-10
WO2001012188A1 (en) 2001-02-22
PL354058A1 (en) 2003-12-15
EP1202734B1 (en) 2007-05-02
HUP0301857A2 (hu) 2003-09-29
CO5200848A1 (es) 2002-09-27
EA200200249A1 (ru) 2002-08-29
EP1202734A1 (en) 2002-05-08
IL147925A0 (en) 2002-08-14
DE60034683T2 (de) 2008-01-17
PE20010482A1 (es) 2001-04-20
EP1202734A4 (en) 2004-09-01
KR20020060158A (ko) 2002-07-16
AR035557A1 (es) 2004-06-16
NO20020687D0 (no) 2002-02-11
NZ517238A (en) 2004-01-30
JP2003507328A (ja) 2003-02-25
CN1379668A (zh) 2002-11-13
HK1049790A1 (zh) 2003-05-30
DE60034683D1 (de) 2007-06-14
NO20020687L (no) 2002-04-03
ZA200201118B (en) 2003-05-28
BR0013277A (pt) 2002-06-18
MXPA02001497A (es) 2003-07-21
AU6747000A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
EP1202734B1 (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6218418B1 (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6863647B2 (en) 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1309590B1 (en) Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6455559B1 (en) Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US20040019046A1 (en) Phenylacetamido-pyrazole derivatives and their use as antitumor agents
SK4732001A3 (en) 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1204649A1 (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
WO2004056827A2 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
US20040116497A1 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
AU2002250840A1 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
MXPA01004277A (en) 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued